Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

NASDAQ:GERN

Geron Corporation

Last Close

4.56

30/08 20:00

Market Cap

2.73B

Beta: 0.91

Volume Today

11.00M

Avg: 5.51M

PE Ratio

−6.06

PFCF: −6.08

Financials Not Available